受强制性开放获取政策约束的文章 - Matus Studeny了解详情
可在其他位置公开访问的文章：3 篇
Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer
JL Dembinski, SM Wilson, EL Spaeth, M Studeny, C Zompetta, I Samudio, ...
Cytotherapy 15 (1), 20-32. e2, 2013
强制性开放获取政策： US National Institutes of Health
Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells
JL Dembinski, EL Spaeth, J Fueyo, C Gomez-Manzano, M Studeny, ...
Cancer gene therapy 17 (4), 289-297, 2010
强制性开放获取政策： US National Institutes of Health
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced …
DH Palmer, YT Ma, M Peck-Radosavljevic, P Ross, J Graham, L Fartoux, ...
British journal of cancer 118 (9), 1162-1168, 2018
强制性开放获取政策： National Institute for Health Research, UK, Wellcome Trust
出版信息和资助信息由计算机程序自动确定